Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib vs Vinorelbine in Malignant Mesothelioma
NCT00597116Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2007
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of vandetanib in malignant mesothelioma (2 arms), sponsored by Sanofi. Primary endpoint: Number of Participants With Disease Control at 2 months. Started Dec 2007; status: terminated.
02
Drugs
vandetanib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00597116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597116.